139. Metal-on-metal hip joint prostheses: a retrospective case series investigating association of systemic toxicity with serum cobalt and chromium concentrations

James Ho, Paul Wax, Jerrold B. Leikin, John R. H. Archer, David M. Wood, Paul I. Dargan, and Jeffrey Brent

Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London, UK; Southwestern School of Medicine, University of Texas, Dallas, USA; Medical Toxicology, Pritzker School of Medicine, Chicago, USA; Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners and Faculty of Life Sciences and Medicine, King’s College London, London, UK; Toxicology Associates, University of Colorado, Denver, USA

Objective: There has been increasing interest in the potential for toxicity associated with metal-on-metal (MoM) hip prostheses. We describe patients referred for outpatient clinical toxicology assessment of potential toxicity related to MoM prostheses.

Case Series: A retrospective review of patients with MoM hip joint prostheses from a specialist outpatient clinical toxicology service in London, UK and, the US Toxicology Investigator’s Consortium (ToxIC) database. Thirty-one cases were identified (17 US, 14 UK); 8 (25.8%) had bilateral MoM prostheses; 3 (9.7%) had bilateral prostheses, of which one was MoM; 20 had unilateral MoM prostheses. All 31 had cobalt concentrations recorded (median peak cobalt concentration 10.0 [IQR 3.8–32.8] mcg/L); chromium concentration was recorded in 25 cases (median peak chromium concentration 6.9 [IQR 3.7–18.7] mcg/L). There was no difference in median concentration between those with unilateral and bilateral MoM for cobalt (10.0 [IQR 2.5–51.4] versus 10.2 [IQR 5.9–18.1] mcg/L; p = 0.73) or chromium (9.1 [IQR 3.4–22.0] versus 6.7 [IQR 5.1–7.2] mcg/L; p = 0.47). Twelve had joint magnetic resonance imaging (MRIs), of whom two (16.7%) had metallosis without correlation with cobalt/chromium concentrations (Fisher’s exact test; p = 0.45 and p = 0.18, respectively). The most commonly reported symptoms were lethargy/malaise and hearing loss (both reported by 9 (29.0%) individuals) (Table 1); the presence of symptoms did not correlate with cobalt/chromium concentrations. Three (9.7%) patients were diagnosed with significant systemic cobalt toxicity: median peak serum cobalt concentration (164.8 [IQR 87.6–630.4] mcg/L) was greater than those without this diagnosis (8.7 [IQR 2.8–18.1] mcg/L), but was not statistically significant (p = 0.056).
Conclusion: In these patients with potential toxicity related to MoM prostheses, although there was a high prevalence of reported symptoms, only three (9.7%) had significant cobalt toxicity. Symptoms did not correlate with peak cobalt/chromium concentrations and whilst cobalt/chromium concentrations were higher in those with systemic toxicity this difference was not statistically significant.